DNA Replication, Cancer and Chemotherapy

Eunice Kennedy Shriver National Institute Of Child Health & Human Development

Investigators

Linked publications, trials & patents

Abstract

June 2, 2022: My progress over the preceding four years was evaluated by the quadrennial NIH Site Visit committee as Outstanding. October 18, 2022: My application for a patent on Autophagy Modulators for Use in Treating Cancer was accepted by the US Patent and Trademark Office (patent number 11,471,460). December 13, 2022: I received an NICHD Lifetime Achievement Award. Recent Publications (2019 to July, 2023) PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells. Roy A, Chakraborty AR, Nomanbhoy T, DePamphilis ML. Autophagy. 2023 Sep;19(9):2464-2484. PMID: 36803256 PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Logue J, Chakraborty AR, Johnson R, Goyal G, Rodas M, Taylor LJ, Baracco L, McGrath ME, Haupt R, Furlong BA, Soong M, Prabhala P, Horvath V, Carlson KE, Weston S, Ingber DE, DePamphilis ML, Frieman MB. Commun Biol. 2022 Aug 12;5(1):808. PMID: 35962188 Cell Death and the p53 Enigma During Mammalian Embryonic Development. Raj S, Jaiswal SK, DePamphilis ML. Stem Cells. 2022 Mar 31;40(3):227-238. PMID: 35304609 Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors. Chakraborty AR, Vassilev A, Jaiswal SK, O'Connell CE, Ahrens JF, Mallon BS, Pera MF, DePamphilis ML. Stem Cell Reports. 2022 Feb 8;17(2):397-412. PMID: 35063131 Developmental Acquisition of p53 Functions. Jaiswal SK, Raj S, DePamphilis ML. Genes (Basel). 2021 Oct 23;12(11):1675. PMID: 34828285 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1. Klionsky DJ et al. See abstract for full author list Autophagy. 2021 Jan;17(1):1-382. PMID: 33634751 CANCER RESEARCH. 2021 Jun 1;81(11):2903-2917. Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells Constandina E O'Connell, Alex Vassilev (work done in M.L. DePamphilis lab) PMID: 33685990 STEM CELLS. 2020 Sep;38(9):1091-1106. Cell cycle arrest and apoptosis are not dependent on p53 prior to p53-dependent embryonic stem cell differentiation Sushil K Jaiswal, John J Oh, Melvin L DePamphilis PMID: 32478947 PLOS ONE. 2020 Mar 31;15(3):e0230670. Efficacy of a small molecule inhibitor of the transcriptional cofactor PC4 in prevention and treatment of non-small cell lung cancer Yan Zhang, Andrei Pavlov, Sohail Malik, Hong Chen, Nancy Kim, Ziqing Li, Xiaohong Zhang, Melvin L DePamphilis, Robert G Roeder, Hui Ge PMID: 32231397 US Patent Application Number 63/119,522 (November 30, 2020) Therapeutics Against Pathogenic Coronaviruses Melvin L. DePamphilis, Arup Chakraborty and Matthew Frieman CANCER RESEARCH. 2019 Oct 1;79(19):4896-4910. The Cdk2-c-Myc-miR-571 Axis Regulates DNA Replication and Genomic Stability by Targeting Geminin Yi Zhang, Zhuqing Li, Qiang Hao, Wei Tan, Jing Sun, Jing Li, Chi-Wei Chen, Zongzhu Li, Yunxiao Meng, Yuan Zhou, Zhiyong Han, Huadong Pei, Melvin L DePamphilis, Wenge Zhu PMID: 31431461 AUTOPHAGY. 2019 Oct;15(10):1694-1718. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis Gaurav Sharma, Carlos M Guardia, Ajit Roy, Alex Vassilev, Amra Saric, Lori N Griner, Juan Marugan, Marc Ferrer, Juan S Bonifacino, Melvin L DePamphilis PMID: 30806145 ONCOGENE. 2019 Mar;38(13):2364-2379. DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2) Chi-Wei Chen, Yongming Li, Shuya Hu, Wei Zhou, Yunxiao Meng, Zongzhu Li, Yi Zhang, Jing Sun, Zhou Bo , Melvin L DePamphilis, Yun Yen, Zhiyong Han, Wenge Zhu PMID: 30518875